Glutamate, Brain Connectivity and Duration of Untreated Psychosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

134 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The early stages of schizophrenia are associated with significant decreases in social and intellectual abilities, with more declines in chronic disease. Studies have identified relationships between duration of untreated psychosis (the duration between the onset of positive symptoms and treatment) and worse long term outcomes. However, the neurobiology of this phenomenon and its implications for response to antipsychotic medications remain poorly understood.

Glutamatergic excess altering brain connectivity might provide an explanation for why those with longer duration of untreated psychosis have worse clinical outcomes. The investigators propose to use neuroimaging to study 67 first episode psychosis subjects before and after sixteen weeks of treatment with risperidone, a common antipsychotic. We will measure (1) glutamate and (2) structural and functional brain connectivity and test the hypotheses that glutamatergic abnormalities are present in first episode patients and that longer duration of untreated psychosis is associated with greater connectivity abnormalities that set the stage for poor response to treatment. 67 demographic-matched controls will also be recruited as a comparison group - healthy controls will not receive antipsychotic medication.

The investigator's previous studies have made progress in the understanding of abnormalities in the glutamate system and brain connectivity in unmedicated patients with schizophrenia and modulation of these by antipsychotic medication. Two indices of glutamatergic dysfunction have been identified. While antipsychotic medications appear to modulate glutamate, the disturbance in the relationship between metabolites is not restored with treatment. In addition, the investigators found that both structural and functional connectivity abnormalities in unmedicated patients with schizophrenia predict patients' response to treatment.

To the investigator's knowledge, no other group has performed a study that uses a combination of complementary neuroimaging techniques that will allow generating a broad characterization of glutamatergic function and brain connectivity in first episode psychosis and change with treatment. The results of the proposed studies could suggest a mechanism by which the duration of untreated psychosis is associated with poor treatment response which might lead to new interventions to target the illness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glutamate, Learning, and Working Memory

NCT02769936

Schizophrenia

COMPLETED PHASE1

Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia

NCT01222793

Schizophrenia Obesity

COMPLETED

Biomarkers in Schizophrenia

NCT00817336

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE2

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE4

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Psychosis Schizoaffective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

first episode psychosis

Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.

Risperidone

Intervention Type DRUG

Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.

healthy demographic-matched controls

healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risperidone

Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Risperdal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons with first episode psychosis
* Healthy controls will be matched to first episode psychosis participants on a one to one basis

Exclusion Criteria

* inability to understand and sign informed consent assessed by the Evaluation to sign Consent form
* diagnosable central nervous system illnesses
* poorly controlled acute or chronic medical conditions aside from psychosis
* history of head trauma with loss of consciousness for \> 2 minutes
* active substance abuse or dependence (exclusive of nicotine dependence)
* suspected substance induced psychotic symptoms
* clinically significant symptoms of depression, hypomania, or mania
* patients concomitantly treated with drugs known to affect glutamate, such as: valproate, topiramate, gabapentin, levetiracetam, lamotrigine, lithium, and acamprosate

Minimum Eligible Age

17 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes